Skip to main content
PharmaTher Holdings Ltd. logo

PharmaTher Holdings Ltd. — Investor Relations & Filings

Ticker · PHRM ISIN · CA71716H1082 LEI · 529900PIPSZ1ZSWF3A21 CSE Manufacturing
Open in API
Filings indexed 188 across all filing types
Latest filing 2025-09-26 Regulatory Filings
Country CA Canada
Listing CSE PHRM

About PharmaTher Holdings Ltd.

https://www.pharmather.com/

PharmaTher Holdings Ltd. is a specialty pharmaceutical company dedicated to the research, development, and commercialization of novel therapeutics, primarily focusing on ketamine and psychedelic compounds. The company's strategy involves advancing three core assets: the KETARX™ portfolio of ketamine drugs, which targets neuropsychiatric and pain disorders; the proprietary PharmaPatch™ microneedle patch platform, designed for the transdermal delivery of ketamine, psychedelics, and GLP-1 drugs; and a 49% ownership interest in Sairiyo Therapeutics Inc., which is developing a patented oral formulation of cepharanthine for infectious diseases and cancer. PharmaTher is focused on achieving regulatory approval for its pipeline candidates to address significant global unmet medical needs in mental health, neurological, and pain disorders.

Recent filings

Filing Released Lang Actions
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 85% confidence The document is a Canadian National Instrument 52-109 Form 52-109FV1 “Certification of Annual Filings” by the CEO, certifying the annual financial statements and MD&A. It is not the actual annual report (10-K) or MD&A itself but a regulatory compliance certificate attached to those filings. It does not announce a report release but serves as a regulatory form. Therefore, it falls into the general regulatory filings fallback category (RNS).
2025-09-26 English
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings Classification · 90% confidence The document is a Form 52-109FV1 Certification of Annual Filings by the issuer’s CFO under Canadian NI 52-109. It is not the actual annual AIF, financial statements, or MD&A, nor an earnings release, dividend notice, or any other specific report type. It is a regulatory compliance filing/certificate and does not fit the specialized categories like 10-K, IR, MDA, or RPA. Thus, it falls under the fallback category Regulatory Filings (RNS).
2025-09-26 English
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 90% confidence The document is Form 13-502F1 filed with the Ontario Securities Commission to report participation fees for a reporting issuer under OSC Rule 13-502. It is a regulatory form submission (fee calculation and certification), not a financial report, dividend notice, M&A document, or investor presentation. It does not fit any of the specific transaction or report categories, so it falls into the general Regulatory Filings category (RNS).
2025-09-26 English
News release - English.pdf
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing PharmaTher’s support for the FDA’s new Commissioner's National Priority Voucher program. It provides business and regulatory update information but is not an earnings release (no financial results), not a formal regulatory filing of financial statements, not a management discussion, dividend notice, or other specific category. It does not represent an attached full report or a proxy statement, and instead is a general corporate announcement. Therefore it falls into the fallback category of Regulatory Filings (RNS).
2025-06-18 English
News release - English.pdf
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing an FDA extension of the review period for its new drug application. It is not an earnings release, capital/financing update, M&A, governance, dividend notice, or any of the other specified categories. It does not present an annual or interim report nor announce the release of a specific financial filing. Therefore, it falls into the fallback “Regulatory Filings” category (Code: RNS).
2025-05-16 English
News release - English.pdf
Regulatory Filings Classification · 80% confidence The document is a corporate press release announcing the FDA’s assignment of a new approval goal date for PharmaTher’s ketamine New Drug Application. It is a regulatory update rather than a financial report, earnings release, or other specific filing. It does not present financial results, proxy materials, management changes, or dividend details. Therefore, it falls under a general regulatory announcement/fallback category.
2025-03-11 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.